

PROJECT TITLE

Choice of Intermittent vs Continual androgens in Prostate Cancer (A CHOICE-PC: Androgens - CHOice of Intermittent vs Continual-Prostate Cancer)

FUNDING

£57,000

Tenovus

RESEARCH QUESTION

What are patient preferences regarding intermittent vs continual androgen deprivation therapy for prostate cancer

RESEARCH DESIGN

Systematic review to synthesis evidence regarding QoL in patients undergoing intermittent androgen deprivation therapy for prostate cancer; Interviews and Discreet Choice Experiment with patients receiving androgen deprivation therapy; UK wide online survey of current practice regarding offering such treatments; A Delphi exercise among cancer specialists to build UK consensus

ABOUT THE STUDY

Prostate cancer is common and increasing. Androgen deprivation is offered as a treatment modality to most men at some point. Side effects are troublesome. It can also increase chances of diabetes, heart disease, memory loss and depression. Risk of recurrence with treatment breaks with careful monitoring is comparable to continual treatment. Hence, offers of treatment breaks are now recommended for suitable patients (NICE) to allow their natural hormones to recover to improve quality of life. It appears, though, they are not offered this choice consistently, especially when older men are reluctant to complain; and when oncologists and surgeons focus more on reducing cancer recurrence risk. Simultaneously, more men are being followed up by their own GP practice, where more education is needed to support men well.

THE TEAM

PhD Student:

Nafees Ud Din: (n.u.din@bangor.ac.uk)

Primary Supervisor:

Clare Wilkinson, Bangor University

Supervisors:

Richard Neal, Bangor University

Eila Watson, Oxford Brooks University

**NWCPCR
Bangor University
Gwenfro Unit 5
Wrexham Technology Park
LL137YP
Tel: 01978 726651/3
Fax: 01978 311419**

